WO2017030167A1 - Agent reconstructeur/activateur de réseau neuronal - Google Patents

Agent reconstructeur/activateur de réseau neuronal Download PDF

Info

Publication number
WO2017030167A1
WO2017030167A1 PCT/JP2016/074130 JP2016074130W WO2017030167A1 WO 2017030167 A1 WO2017030167 A1 WO 2017030167A1 JP 2016074130 W JP2016074130 W JP 2016074130W WO 2017030167 A1 WO2017030167 A1 WO 2017030167A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
group
extract
naringenin
food
Prior art date
Application number
PCT/JP2016/074130
Other languages
English (en)
Japanese (ja)
Inventor
千尋 東田
かつ子 小松
Original Assignee
レジリオ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レジリオ株式会社 filed Critical レジリオ株式会社
Priority to JP2017503639A priority Critical patent/JP6165380B1/ja
Publication of WO2017030167A1 publication Critical patent/WO2017030167A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus

Definitions

  • the present invention relates to agents, compositions, and foods useful for the treatment of neurological diseases, improvement of memory ability, extension of nerve axons, and the like.
  • Naringenin is a component contained in grapefruit and the like, and is considered to be a component having an antioxidant effect and the like.
  • Non-Patent Document 1 naringenin is effective in the treatment of Alzheimer's disease (Non-Patent Document 1), but its mechanism and action mechanism have not been clarified.
  • the herbal medicine bone crush (Katsusaiho) is a rhizome of the sea urchinaceae Hakamauraboshi, and is known to contain naringenin, but the traditional effects of bone crushing are as follows: Although anti-inflammation, muscular bone pain, tinnitus, toothache and the like are known (for example, Patent Document 1), the relationship between osteoclastic prosthesis and its active ingredient and the neural circuit is not known at all.
  • Ezokogi is a plant belonging to the family Uleaceae that grows naturally in Hokkaido, etc., and is considered to have a tonic effect.
  • An object of the present invention is to provide a novel agent, composition, and food and drink useful for prevention / treatment of neurological diseases, improvement / improvement of memory ability and cognitive function, and the like.
  • ⁇ ⁇ Neurodegenerative diseases such as Alzheimer's disease, senile dementia, cerebrovascular dementia, and Parkinson's disease all have different etiologies, but all indicate symptoms that impair memory and cognition due to the breakdown of the neural network.
  • these diseases for which there is no effective therapeutic method, there is a real need for a treatment that can bring the nerve function closer to normal even when the nerve network has already been impaired.
  • treatment with less burden is more desirable than nerve cell transplantation and gene therapy that require surgery. Therefore, it is desired to develop a drug that regenerates a neural network even when a nerve cell is damaged or after it has been damaged.
  • amyotrophic lateral sclerosis is an intractable disease in which the limbs of the cerebral cortex motor cortex and the motor neurons of the spinal cord and brainstem drop off, and there is no effective treatment. Furthermore, motor neurons in the cerebral cortex motor cortex are also damaged by cerebral hemorrhage, cerebral infarction, brain tumor, brain trauma, etc., leading to paralysis of the body. Traumatic spinal cord injury also results in limb paralysis due to damage to spinal motor neurons.
  • multiple cerebral infarction is a demyelinating disease of the central nervous system caused by abnormal activation of autoimmunity, but axonal loss occurs as the disease progresses, which is an irreversible malfunction of the neural network. Leads to. In either case, it is a dysfunction due to the breakdown of the neural network, but if the surviving nerve cells are activated to form a neural network again, recovery of the function can be expected.
  • the present inventor asked herbal medicines for a component exhibiting excellent activity for improving the atrophy / degeneration of nerve axons in the brain that has become degenerated and dysfunctional.
  • naringenin and herbal medicine ingredients containing such specific ingredients (such as osteoclastic components)] and sorghum ingredients are effective in repairing neurites and improving memory impairment.
  • Such functions also lead to the prevention and treatment of neurological diseases. Therefore, the specific component and the sorghum component (particularly a combination of these) are used for the prevention and treatment of neurological diseases, memory ability.
  • the present inventors have obtained knowledge that it is effective for use in improving cognitive function and for repairing and extending neurites, and have further studied based on this knowledge to complete the present invention.
  • the agent of the present invention comprises at least one component (A) selected from naringenin, eriodictyol, 5,7-dihydroxychromone, caffeic acid, protocatechuic acid, glycosides thereof, and salts thereof.
  • component (A) selected from naringenin, eriodictyol, 5,7-dihydroxychromone, caffeic acid, protocatechuic acid, glycosides thereof, and salts thereof.
  • Such an agent of the present invention may be an agent for use in at least one application selected from the following (1), (2) and (3).
  • (1) Neurite repair and / or extension (growth) (2) Improvement or improvement of memory and / or cognitive function (3) Prevention and / or treatment of neurological diseases
  • such an agent of the present invention usually contains only naringenin as an active ingredient and often does not contain an agent for the prevention and / or treatment of Alzheimer's disease.
  • the component (A) may contain, for example, at least one component selected from naringenin, a glycoside of naringenin (for example, naringin, naringen glucuronide), and salts thereof.
  • the agent of the present invention may contain an osteoclastic component (such as an osteoclastic extract) as a component containing the component (A).
  • an osteoclastic component such as an osteoclastic extract
  • the agent of the present invention may be used in combination of the component (A) and the component (B), and particularly may contain the component (A) and the component (B).
  • the agent of the present invention contains a bone crush extract as the component (A) and a carp extract as the component (B), and the ratio of the bone crush extract and the carp extract is the former /
  • the latter (weight ratio) 1 / 0.01 to about 1/100 may be used.
  • the agent of the present invention may further combine at least one component (C) selected from diosgenins (such as diosgenin and diosine), dihydroxyvitamin D3, and desonomin.
  • the component (C) may be a different agent from the component (A) and the component (B), or may be an agent (mixture) containing the component (A) and the component (B).
  • the present invention includes at least one component (A) selected from naringenin, eriodictyol, 5,7-dihydroxychromone, caffeic acid, protocatechuic acid, glycosides thereof, and salts thereof, and an elephant component A composition containing (B) is also included.
  • a composition may be a pharmaceutical composition.
  • the component (A) may contain, for example, at least one or more components selected from naringenin, glycosides of naringenin (eg, naringin, naringen glucuronide), and salts thereof. .
  • composition of the present invention may contain an osteoclastic component (such as an osteoclastic extract) as the component containing component (A).
  • an osteoclastic component such as an osteoclastic extract
  • the composition of the present invention may further combine at least one component (C) selected from diosgenins (such as diosgenin and diosine), dihydroxyvitamin D3, and desonomin.
  • the component (C) may be a composition different from the component (A) and the component (B), or may be a composition containing the component (A) and the component (B).
  • composition of the present invention may be a composition for use in at least one application selected from the following (1), (2) and (3).
  • Included in the present invention are foods and drinks containing the above-mentioned agent (particularly, an agent in which component (A) and component (B) are combined) or the composition of the present invention.
  • Such foods and drinks may be supplements, health foods, functional indication foods, nutritional functional foods, or foods for specified health use.
  • the food or drink of the present invention may be a food or drink containing 1 to 90% by weight of the osteoclast extract, or a food or drink containing 1 to 90% by weight of the elephant extract.
  • Such a food or drink may contain at least one component (C) selected from diosgenins (such as diosgenin and diosin), dihydroxyvitamin D3, and desonomin.
  • component (C) selected from diosgenins (such as diosgenin and diosin), dihydroxyvitamin D3, and desonomin.
  • the proportion of component (C) may be, for example, about 1 to 90% by weight.
  • the neural network can be reconstructed and / or activated.
  • Such reconstruction and activation are usually accompanied by repair and / or extension (extension) of neurites (axons, dendrites, etc.). Therefore, the agent or composition of the present invention is useful for preventing, treating or improving various neurological diseases caused by degeneration or atrophy of axons and dendrites, as well as improvement or improvement (enhancement) of the cognitive memory function. It is valid.
  • the improvement of the memory ability in the cognitive function is recognized in the agent and composition of the present invention, regardless of whether or not it leads to a neurological disease, the ingredients of the food and drink for the purpose of improving and improving the memory ability, etc. It is also useful.
  • FIG. 1 is a diagram showing an axonal extension action by a bone crush extract and a bone crush component on normal cerebral cortical neurons.
  • FIG. 2 is a diagram showing an axonal re-extension effect when a crushed prosthetic component is later treated against A ⁇ (25-35) -induced axonal atrophy in cerebral cortical neurons.
  • FIG. 3 is a diagram showing the area of amyloid plaques in the prefrontal cortex of 5XFAD mice administered with a bone fracture supplement for 31 days.
  • FIG. 4 is a diagram showing the area of the degenerated axon terminal area in the prefrontal cortex of 5XFAD mice administered with the osteoclastic prosthesis for 31 days.
  • FIG. 1 is a diagram showing an axonal extension action by a bone crush extract and a bone crush component on normal cerebral cortical neurons.
  • FIG. 2 is a diagram showing an axonal re-extension effect when a crushed prosthetic component is later treated against A ⁇ (25-35)
  • FIG. 5 is a diagram showing the area of amyloid plaques in the peri-olfactory cortex of 5XFAD mice to which the osteoclastic extract was administered for 31 days.
  • FIG. 6 is a diagram showing the area of the degenerated axon terminal area in the perianptic cortex of 5XFAD mice administered with the osteoclastic extract for 31 days.
  • FIG. 7 is a diagram showing the area of amyloid plaques in the hippocampal CA1 region of 5XFAD mice administered with the osteoclastic prosthesis for 31 days.
  • FIG. 8 is a diagram showing the area of the degenerated axon terminal area in the hippocampal CA1 region of 5XFAD mice administered with the osteoclastic prosthesis for 31 days.
  • FIG. 6 is a diagram showing the area of the degenerated axon terminal area in the hippocampal CA1 region of 5XFAD mice administered with the osteoclastic prosthesis for 31 days.
  • FIG. 9 is a diagram showing the area of amyloid plaques in the hippocampal dentate gyrus region of 5XFAD mice to which the osteoclastic extract was administered for 31 days.
  • FIG. 10 is a diagram showing the area of the degenerated axon terminal area in the hippocampal dentate gyrus region of 5XFAD mice administered with the osteoclastic prosthesis for 31 days.
  • FIG. 11 is a diagram showing the level of phosphorylation of threonine of the 514th amino acid of CRMP2 in the cerebral cortex of 5XFAD mice administered with the osteoclastic extract for 22 days.
  • FIG. 12 is a diagram showing an axonal re-extension effect when a fraction of the osteoclastic extract is treated later against A ⁇ (25-35) -induced axonal atrophy in cerebral cortical neurons.
  • FIG. 13 is a diagram showing an LC-MS chart of the n-butanol fraction of the osteoclastic extract.
  • FIG. 14 is a diagram showing the axonal re-extension effect when a compound contained in the osteoclastic extract is later treated against A ⁇ (25-35) -induced axonal atrophy in cerebral cortical neurons.
  • FIG. 12 is a diagram showing an axonal re-extension effect when a fraction of the osteoclastic extract is treated later against A ⁇ (25-35) -induced axonal atrophy in cerebral cortical neurons.
  • FIG. 15 is a diagram showing the results of an object recognition memory test in 5XFAD mice administered with a bone crush extract, or an extract of Ekokogi leaves, or a combination of an osteoclastic extract and an extract of Ekokogi leaves for 15 days.
  • FIG. 16 is a diagram showing the results of an object recognition memory test in normal mice administered with Ezocogi leaf extract for 27 days.
  • the agent or composition of the present invention comprises a specific component (A) or an sorghum component (B).
  • Such an agent or composition (and food or drink) of the present invention is useful for the reconstruction and / or activation of a neural network.
  • the agent or composition of the present invention often has a function of repairing or extending (extending) neurites [particularly atrophy or deficient neurites (axons or dendrites)].
  • the agent or composition of the present invention is often associated with such a function, or has an effect of improving or improving memory ability and / or cognitive function, and an effect of preventing and / or treating a neurological disease. .
  • the agent or composition of the present invention may be suitably used for at least one application selected from the following (1), (2), and (3).
  • Neurological diseases especially nerves And / or treatment of neurological diseases associated with atrophy or loss of processes (axons and dendrites)
  • the neurological disease may be a traumatic neurological disease or a neurodegenerative disease.
  • Alzheimer's disease dementia (non-Alzheimer type dementia such as senile dementia, Cerebrovascular dementia, Pick's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, etc.), Parkinson's disease, Huntington's disease, brain contusion, spinal cord injury, amyotrophic lateral sclerosis, multiple occurrences Include cerebral infarction.
  • dementia non-Alzheimer type dementia such as senile dementia, Cerebrovascular dementia, Pick's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, etc.
  • Parkinson's disease Huntington's disease
  • brain contusion spinal cord injury
  • amyotrophic lateral sclerosis multiple occurrences Include cerebral infarction.
  • agent or composition of the present invention may prevent or treat one or more neurological diseases.
  • Component (A) consists of naringenin, eriodictyol, 5,7-dihydroxychromone, caffeic acid, protocatechuic acid, glycosides thereof [or glycosides (O-glycosides)], and salts thereof (especially pharmaceutically acceptable) Selected salt).
  • the sugar constituting the glycoside is not particularly limited, and is a monosaccharide [eg, glucose, galactose, apiose, rhamnose, xylose, uronic acid (glucuronic acid, etc.)], disaccharide (eg, rutinose, neohesperidose, etc.) , Gentiobiose, etc.), and sugars to which these sugars are bonded.
  • a monosaccharide eg, glucose, galactose, apiose, rhamnose, xylose, uronic acid (glucuronic acid, etc.)
  • disaccharide eg, rutinose, neohesperidose, etc.
  • Gentiobiose etc.
  • the glycoside may be bound with one or more sugars.
  • glycosides include, for example, naringenin glycoside [eg, naringenin glucoside (eg, naringenin-7-glucoside, naringenin-4-glucoside, etc.), naringening glucuronide (eg, naringenin-4-glucuronide, naringenin- 4-glucuronide etc.), naringenin rutinosides (eg naringin etc.)], eriodictyol glycosides [eg eriodictyol rutinosides (eg neoeriocitrin etc.)], 5,7-dihydroxychromone Glucose [eg, 5,7-dihydroxychromone neohesperidoside (eg, 5,7-dihydroxychromone-7-neohesperidoside, etc.)], caffeic acid glycoside [eg, caffeic acid glucoside
  • the salt is not particularly limited, and examples thereof include metal salts [for example, alkali metal salts (for example, lithium salt, sodium salt, potassium salt), alkaline earth metal salts (for example, magnesium salt, calcium salt), periodic table, etc. Group 13 metal salts (for example, aluminum salts), transition metal salts (for example, salts such as zinc), etc.] ammonium salts, amine salts [for example, alkylamine salts (for example, trialkylamine salts, trialkylamine salts of triethylamine salts) ), Alkanolamine salts (for example, monoethanolamine salts, triethanolamine salts), cyclic amine salts (for example, pyridine salts)] and the like.
  • metal salts for example, alkali metal salts (for example, lithium salt, sodium salt, potassium salt), alkaline earth metal salts (for example, magnesium salt, calcium salt), periodic table, etc.
  • Group 13 metal salts for example, aluminum salts), transition metal salts (for example,
  • Component (A) may contain one or more components. When component (A) contains two or more components, it may contain two or more components that are common in the basic skeleton (for example, including naringenin and naringenin glycoside), and combinations of components having different basic skeletons 2 or more may be included (for example, having a combination of naringenin or its glycoside and eriodictyol or its glycoside).
  • component (A) may contain one or more components.
  • component (A) may contain two or more components that are common in the basic skeleton (for example, including naringenin and naringenin glycoside), and combinations of components having different basic skeletons 2 or more may be included (for example, having a combination of naringenin or its glycoside and eriodictyol or its glycoside).
  • component (A) is typically at least one component selected from naringenin, a glycoside of naringenin (naringin, naringen glucuronide, etc.), and salts thereof (collectively, naringenins) May be included) at least.
  • the component (A) may be synthesized or derived from a natural product.
  • a synthesis method a conventional method can be used.
  • Naringenin and Naringin are known to be contained in citrus plants (citrus plants such as grapefruit and hassaku), and the component (A) may be obtained from such plants.
  • osteoclasts often contain other components (A) in addition to naringenin, etc., and in combination with these, the effects of the present invention are effectively expressed.
  • A components in addition to naringenin, etc.
  • the agent of the present invention may contain a bone crush prosthetic component as a component containing the component (A).
  • osteoclastic component examples include osteoclastic prosthesis, osteoclastic extract (osteoclast extract) and the like, and these may be combined.
  • a commercially available product may be used as the osteoclastic extract, and the osteoclastic extract is extracted by a conventional method ⁇ for example, using an extraction solvent [for example, water, alcohol (methanol, ethanol, etc.), a mixture thereof, etc.]]. It can also be obtained by subjecting to extraction at ordinary temperature or under heating by a conventional method or a method according thereto.
  • an extraction solvent for example, water, alcohol (methanol, ethanol, etc.), a mixture thereof, etc.
  • a part having a high content or concentration of component (A) may be separated or fractionated.
  • an aqueous solvent extract of osteoclast for example, an extract using water, a mixed solvent of water and alcohol as an extraction solvent
  • an alcohol for example, n-butanol and the like having 3 or more carbon atoms (for example, n-butanol)
  • Processed products obtained by separation or fractionation by extraction or the like with an alcohol having about 4 to 6 carbon atoms often contain a high content of component (A) containing naringenin. You may use a processed material suitably.
  • the osteoclastic prosthesis may be used as it is or after being crushed (crushed).
  • the extract may be further subjected to concentration and drying (room temperature drying, freeze drying, etc.).
  • the form of the osteoclastic component is not particularly limited, but may be, for example, powder (or powder).
  • Ezokogi component (B) examples of the Ekokogi component (B) include Ezoukogi, Ezoukogi extract (Ezoukogi extract), and the like.
  • Ezoukogi scientific name: Eleutherococcus senticosus, Acanthopanax senticosus (Rupr. May be used, these may be used in combination, or the whole plant may be used.
  • At least the leaves of Ezokogi may be suitably used.
  • the Ekokogi extract may be a commercially available product or can be obtained by extracting Ezokogi by a conventional method.
  • the extraction solvent examples include water, alcohol [eg, alkanol (eg, C 1-4 alkanol such as methanol, ethanol, isopropanol, n-butanol), polyol (eg, ethylene glycol, propylene glycol, 1,3-butylene]. Glycol, glycerin, etc.), ketones (eg, acetone, methyl ethyl ketone, etc.), ethers (eg, diethyl ether, etc.), esters (eg, ethyl acetate, etc.) and the like. You may use an extraction solvent individually or in combination of 2 or more types. Typical extraction solvents include water, alcohol (such as ethanol), a mixed solution thereof, and the like.
  • alkanol eg, C 1-4 alkanol such as methanol, ethanol, isopropanol, n-butanol
  • polyol eg, ethylene glycol, propylene glycol, 1,
  • Extraction temperature and extraction time are not particularly limited and can be appropriately selected according to the extraction solvent, extraction method, and the like.
  • the elephant may be subjected to an appropriate treatment (pulverization treatment, heat treatment, drying treatment, etc.) as necessary.
  • the extract may be further subjected to concentration and drying (room temperature drying, freeze drying, etc.).
  • the form of the Ekokogi component is not particularly limited, but may be powdery (or powdery).
  • component (C) In the agent or composition of the present invention, component (A) and / or component (B) may be combined with diosgenins, dihydroxyvitamin D3, desonomin and the like. By combining with these components (hereinafter, these may be referred to as component (C)), the effects of the present invention may be realized more efficiently.
  • component (C) may be composed of at least diosgenins.
  • diosgenins include diosgenin, diosgenin derivatives, and salts thereof.
  • diosgenin derivative a compound in which the hydroxyl group at the C3 position of diosgenin is substituted, a compound having a substituent at the C2 position (or a compound having a hydrogen atom at the C2 position substituted), a compound having a substituent at the C4 position (or C4) Compound having a hydrogen atom at the position), a compound having a substituent at the C6 position (or a compound having the hydrogen atom at the C6 position substituted) [for example, ester derivatives of the hydroxyl group at the C3 position (for example, amino acid derivatives, aminosulfones) Acid derivatives, carbamate derivatives), halogenated derivatives of the hydroxyl group at the C3 position, etc.], and glycosides thereof.
  • diosgenin derivative examples include a compound represented by the following formula (I-1), a glycoside of diosgenin or a compound represented by the following formula (I-1), and the like.
  • R 1 , R 2 , R 3 and R 4 are the same or different and represent a hydrogen atom or a substituent. However, when R 2 , R 3 and R 4 are hydrogen atoms, R 1 is hydroxyl. Not a group.
  • the substituent includes a hydrocarbon group ⁇ eg, alkyl group [eg, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group, t-butyl group].
  • alkyl group eg, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group, t-butyl group.
  • alkyl group such as pentyl group (eg C 1-12 alkyl group, preferably C 1-8 alkyl group)], cycloalkyl group (eg cyclopentyl group, cyclohexyl group, cycloheptyl) Group, a C 4-10 cycloalkyl group such as a cyclooctyl group, preferably a C 5-8 cycloalkyl group), an aralkyl group (for example, a C 6-10 aryl C 1-4 alkyl group such as a benzyl group or a phenethyl group) Saturated with a polycyclic aliphatic hydrocarbon group (for example, a decalinyl group, a norbornyl group, an adamantyl group, a dimethyladamantyl group, etc.) Saturated aliphatic hydrocarbon group; an aryl group (e.g., phenyl group, a to
  • R a is a hydrocarbon group (eg, the exemplified hydrocarbon group such as an alkyl group), and R b is a hydrogen atom or a hydrocarbon group (eg, the exemplified hydrocarbon group such as an alkyl group).
  • R c is a sugar (or sugar chain or sugar residue)
  • R d is an alkylene group (eg, C 2-4 alkylene group such as ethylene group, propylene group, trimethylene group, etc.)
  • R e is a hydrogen atom, hydroxyl group A group or a hydrocarbon group (for example, the above exemplified hydrocarbon group such as an alkyl group (such as a methyl group))
  • k represents an integer of 2 or more (for example, 2 to 10)
  • R a and R b are the same Or they may be different groups, and when R b is plural, they may be the same or different.
  • the hydrocarbon group may further have a substituent.
  • the substituent is not particularly limited, but includes the above-exemplified substituents, for example, an oxygen atom-containing group (for example, a hydroxyl group, a carboxyl group, a group —OR a , a group —O—CO—R a, etc.), a nitrogen atom-containing group A group (for example, an amino group, a group —NR a R b ), a sulfur atom-containing group (for example, a mercapto group, a group —SR a , a sulfo group, a group —SO 2 —R b, etc.).
  • an oxygen atom-containing group for example, a hydroxyl group, a carboxyl group, a group —OR a , a group —O—CO—R a, etc.
  • a nitrogen atom-containing group A group for example, an amino group, a group —NR a R
  • the hydrocarbon group may have these substituents alone or in combination of two or more.
  • the number of substituents may be 1 or more, for example, 1 to 10 (eg, 1 to 8), preferably 1 to 6 (eg, 1 to 4), Preferably, it may be about 1 to 3.
  • R 1 When R 1 is a substituent, representative R 1 includes, for example, a hydrocarbon group [eg, alkyl group (eg, group — (CH 2 ) n —CH 3 ), cycloalkyl group, aralkyl group, etc.] , Heteroatom-containing groups ⁇ eg oxygen atom-containing groups [eg hydroxyl groups, groups —O— (CH 2 ) n —CH 3 , groups —O— (CH 2 ) m —NH 2 , groups —O— (CH 2 ) m —COOH, group —O— (CH 2 ) m —SO 3 H, group —O—CO— (CH 2 ) n —CH 3 , group —O—CO—NH— (CH 2 ) n —CH 3 , group —O—CO—NR— (CH 2 ) n —CH 3 , group —O—CO—NH—CH (R b ) —COOH, group
  • m is an integer of 1 or more (eg, 1 to 10, preferably 1 to 4, more preferably 1 or 2), and n is an integer of 0 or more (eg, 0 to 10, preferably 0 to 2). 7) and R b is the same as the above [that is, a hydrogen atom or a hydrocarbon group (for example, an alkyl group, etc.)].
  • examples of the substituent include the same substituents as those exemplified in the section of R 1 .
  • typical examples of the substituent include an oxygen atom-containing group, a nitrogen atom-containing group, a sulfur atom-containing group, an amino acid group, and a halogen atom.
  • R 3 is a substituent, typical substituents include a halogen atom.
  • combinations of R 1 to R 4 are not limited, and all combinations are included.
  • Typical combinations of R 1 to R 4 include, for example, the following combinations. (1) A combination in which R 1 is a substituent other than a hydroxyl group, and R 2 to R 4 are hydrogen atoms. (2) R 1 is a substituent other than a hydroxyl group, R 2 is a substituent, R 3 and R 4 are hydrogen.
  • diosgenin derivatives include, for example, the following formula (II) (3 ⁇ , 25R) -3- (2-aminoethanoyloxy) -spirost-5-ene ⁇ (3 ⁇ , 25R) -3- (2-Aminoethanoyloxy) -spirost-5-ene ⁇ , represented by the following chemical formula ( III) (3 ⁇ , 25R) -3-fluorospirost-ene ⁇ (3 ⁇ , 25R) -3-Fluorospirost-5-ene ⁇ represented by the formula (3 ⁇ , 25R) -3- (2-aminoethylsulfonyloxy) -Spirost-5-ene ⁇ (3 ⁇ , 25R) -3- (2-Aminoethylsulfonyl-oxy) -spirost-5-ene ⁇ , (3 ⁇ , 25R) -3- (2-aminopropylsulfonyloxy) -spirost-5 -Ene, (3 ⁇ , 25
  • glycoside examples include diosgenin or a compound in which R 1 is a hydroxyl group in the above formula (I-1) and a sugar (such as the sugar exemplified above) is bonded to a hydroxy group (for example, diosine).
  • salts include hydrohalides (for example, hydrofluorates, hydrochlorides, hydrobromides, hydroiodates, etc.) and inorganic acid salts.
  • hydrohalides for example, hydrofluorates, hydrochlorides, hydrobromides, hydroiodates, etc.
  • inorganic acid salts include hydrohalides (for example, hydrofluorates, hydrochlorides, hydrobromides, hydroiodates, etc.) and inorganic acid salts.
  • organic carboxylates eg acetate, oxalate, maleate, tartrate, fumarate, citric acid Acid salts
  • organic sulfonates eg methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, camphorsulfonate, etc.
  • amino acid salts eg aspartic acid) Salt, glutamate, etc.
  • diosgenins include diosgenin, compounds represented by the above formula (I-1), diosin, and salts thereof.
  • Particularly preferred diosgenins include diosgenin, a compound represented by the formula (II), a compound represented by the formula (III), diosine, and salts thereof.
  • the agent or composition of this invention should just contain any one of a component (A) and a component (B), and may combine a component (A) and a component (B). Usually, in the composition of this invention, you may combine a component (A) and a component (B). By combining the component (A) and the component (B), it is easier to obtain a memory improvement effect and the like.
  • a component (A) and a component (B) are good also as another agent or a composition, and the agent (A) containing a component (A) and a component (B) ( A mixture) or a composition may be used.
  • the said ratio is a ratio of an active ingredient (or solid content) conversion.
  • agent or composition is not particularly limited, and component (A) and / or component (B) may be used as an agent (for example, powder) or composition as it is, and other components (carrier, excipient, etc.). You may formulate with it.
  • excipients for example, excipients, binders, disintegrants, coating agents, lubricants, colorants, flavoring agents, and if necessary, stabilizers, emulsifiers, absorption enhancers, surfactants,
  • a pH adjusting agent, preservative, antioxidant and the like can be used, and it can be formulated by a conventional method by incorporating components generally used as a raw material of the formulation.
  • the component (carrier) used for the formulation is not particularly limited, but for example, animal and vegetable oils such as soybean oil, beef tallow and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane and solid paraffin; octyldodecyl myristate, myristic acid Ester oil such as isopropyl; Higher alcohol such as cetostearyl alcohol and behenyl alcohol; Silicone resin; Silicone oil; Polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, poly Surfactants such as oxyethylene polyoxypropylene block copolymer; hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol Water-soluble polymers such as ethanol, polyvinylpyrrolidone and methylcellulose; lower alcohols such as ethanol and isopropanol; polyhydr
  • excipients examples include lactose, corn starch, sucrose, glucose, mannitol, sorbitol, crystalline cellulose, silicon dioxide and the like.
  • binder examples include polyvinyl alcohol, gelatin, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl acetal diethylaminoacetate, corn starch and the like.
  • disintegrant examples include corn starch, low-substituted hydroxypropylcellulose, crospovidone, crystalline cellulose, precipitated calcium carbonate, croscarmellose sodium, calcium citrate, dextrin, pectin, carboxymethylcellulose calcium and the like.
  • lubricant examples include magnesium stearate, talc, polyethylene glycol, light anhydrous silicic acid, sucrose fatty acid ester, and the flavoring agents include cocoa powder, menthol, aroma powder, mint oil, dragonfly, For example, cinnamon powder is used.
  • agent or composition of the present invention may be further combined with another component useful for improving neurological diseases and memory as long as the effects of the present invention are not impaired.
  • another component useful for improving neurological diseases and memory as long as the effects of the present invention are not impaired.
  • the aspect used separately from an agent or a composition other than the aspect contained in an agent or a composition is mentioned.
  • Examples of the form (dosage form) of the agent or composition of the present invention include tablets, powders, fine granules, granules, dry syrups, coated tablets, orally disintegrating tablets, chewable tablets, capsules, soft capsules, and syrups.
  • Agent oral solution, troche, jelly, inhalant, suppository, injection, ointment, eye drop, eye ointment, nasal drop, ear drops, poultice, lotion, external solution, spray, External aerosols, creams, gels, tapes, buccal tablets, sublingual tablets, vaginal suppositories, vaginal tablets, rectal soft capsules and the like can be mentioned.
  • the administration (taking) form of the agent or composition of the present invention is not particularly limited, and may be oral administration or parenteral administration.
  • Parenteral administration includes, for example, rectal administration, nasal administration, pulmonary administration, injection administration (eg, intravenous administration, intrathecal administration, intraepidural administration, intramuscular administration, subcutaneous administration, intraperitoneal administration)
  • Intraarterial administration eg, intravenous administration, intrathecal administration, intraepidural administration, intramuscular administration, subcutaneous administration, intraperitoneal administration
  • a typical administration form is oral administration.
  • component (A) and / or component (B) contained in the agent or composition of the present invention is not particularly limited, and is preferably a dose sufficient to obtain a desired effect.
  • the dose varies depending on, for example, the degree of symptom, age, sex, body weight, dosage form, salt type, specific type of disease, etc., but usually per day, component (A) and / or Component (B) may be about 0.01 to 100 mg / kg, preferably about 0.1 to 10 mg / kg, more preferably about 0.5 to 5 mg / kg.
  • the dose (intake, dose) of component (A) is 0.01 to 100 mg / kg, preferably 0.1 to 10 mg / kg, more preferably 0.5 to 5 mg / kg per day. It may be a degree.
  • the dosage (intake, dose) of the osteoclastic extract is 10 to 2000 mg / kg, preferably 20 to 1000 mg / kg, more preferably 50 to 100 per day. It may be about 800 mg / kg (for example, 100 to 700 mg / kg).
  • the dose (intake, dose) of component (B) is 10 to 2000 mg / kg, preferably 20 to 1000 mg / kg, more preferably 50 to 800 mg / kg per day ( For example, it may be about 100 to 700 mg / kg).
  • the dose (intake, dose) of the component (C) is 0.01 to 100 mg / kg, preferably 0.1 to 10 mg / kg per day. More preferably, it may be about 0.5 to 5 mg / kg.
  • Administration may be divided once or multiple times.
  • kit comprising a container such as a pack or a dispenser device that may contain one or more unit dosage forms containing component (A) and / or component (B). Good.
  • kits may be composed of a container containing an agent or composition containing component (A) and a container containing an agent or composition containing component (B).
  • kits typically include containers for containing separate agents or compositions, such as split bottles or split foil packets, but include the separate compositions in a single unsplit container. You can also. Kit forms are particularly useful when different components are administered in different dosage forms, when separate components are administered at different dosage intervals, or when the combined individual components need to be titrated by the prescribing physician. is there.
  • Packs can include, for example, metal or plastic foil, blister packs and the like.
  • Blister packs are well known in the packaging industry and are widely used for packaging pharmaceutical unit dosage forms (tablets, capsules, etc.).
  • Blister packs generally consist of a sheet of relatively hard material covered by a foil of transparent plastic material.
  • recesses are formed in the plastic foil. These indentations are tailored to the size and shape of the individual tablets or capsules to be packed.
  • the tablet or capsule is then placed in the recess and the sheet of relatively hard material is sealed against the plastic foil at the foil surface opposite to the direction in which the recess was formed.
  • the strength of the sheet is preferably such that the tablet or capsule can be removed from the blister pack by manually applying pressure to the recess so that an opening is formed in the sheet at the location of the recess. Tablets or capsules can be removed through the opening.
  • Package or dispenser device can be accompanied by package inserts, product inserts, etc. for administration.
  • Containers such as packs or dispensers can be adapted to the notifications of government agencies and authorities that regulate the manufacture, use or sale of medicines.
  • the present invention includes foods and drinks containing the component (A), the component (B) (and other components such as the component (C)) (that is, foods and drinks containing the agent or composition).
  • foods and drinks containing the component (A), the component (B) (and other components such as the component (C)) that is, foods and drinks containing the agent or composition).
  • preferred embodiments of the component (A) and the component (B), the ratio thereof, and the like are the same as described above.
  • foods and drinks also include health foods such as foods for specified health use and foods with nutrient function specified by the Ministry of Health, Labor and Welfare.
  • Nutritional supplements feed, food additives, and the like are also included in the food and drink of the present invention.
  • the food and drink may be food or drink for a specific subject [for example, for elderly people, patients or patients (for example, for patients having a neurological disease (such as the above-described neurological diseases)]). Good.
  • component (A) and / or the component (B) In order to use the component (A) and / or the component (B) in foods and drinks, it is necessary to produce foods and drinks as they are or together with various nutritional components and the like in raw materials for foods and drinks such as processed meat and soft drinks. it can.
  • the components (A) and / or (B) are used as health foods, dietary supplements, etc., for example, using conventional means, tablets, capsules (soft capsules, hard capsules, etc.), powders, granules, liquids (Suspensions, syrups, etc.), emulsions, jellies, sticks, etc.
  • the tablet includes a disintegrating tablet (orally disintegrating tablet).
  • the food and drink may contain a food additive (food additive) as long as it contains bone fracture supplement or an extract of bone fracture supplement.
  • a food additive for example, excipient
  • fillers for example, wheat starch, corn starch, cellulose, lactose, sucrose, mannitol, sorbitol, xylitol, pregelatinized starch, casein, magnesium aluminate silicate, Calcium silicate, etc.
  • binder eg, pregelatinized starch, hydroxypropylmethylcellulose, polyvinylpyrrolidone, etc.
  • disintegrant eg, cellulose, hydroxypropylcellulose, corn starch, etc.
  • fluidizing agent eg, light anhydrous silicic acid
  • oils eg, vegetable oils such as soybean oil, sesame oil, olive oil, linseed oil, sesame oil, rapeseed oil, coconut oil, corn oil, etc.
  • nutrients
  • Food additives may be used alone or in combination of two or more, and in particular, two or more may be used.
  • two or more components for example, two or more components selected from the components classified as excipients
  • the additive may be a combination of different additives.
  • At least two or more additives selected from excipients, binders, and disintegrants may be used.
  • the food or drink is not particularly well-maintained.
  • food e.g., noodles (such as soba, udon, Chinese noodles, instant noodles), Confectionery (cake, candy, gum, chocolate, snacks (potato chips, etc.), biscuits, cookies, gummy, jelly, jam, butter, cream (cream puffs, cakes, etc.), breads, marine or livestock processed foods (kamaboko) , Ham, sausage, etc.), dairy products (processed milk, fermented milk, etc.), fats and oils and processed foods (salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing, etc.), seasonings (sauce, sauce, etc.) , Retort food (curry, stew, rice cake, porridge, miscellaneous food, etc.), frozen dessert (ice cream, sha Bet, etc. shaved ice), fried (cro
  • the amount of component (A) and / or component (B) in the above-mentioned food and drink varies depending on the addition form and administration form, and can be selected from a wide range, for example, 0.001 to 90% by weight, preferably 0. 001 to 80% by weight, more preferably 0.1 to 70% by weight (eg 1 to 50% by weight), usually 0.01 to 50% by weight (eg 0.1 to 30% by weight) Also good.
  • the proportion of the bone crush extract is 1 to 90% by weight, preferably 10 to 70% by weight, more preferably about 20 to 50% by weight. May be.
  • the ratio of the extract is, for example, 1 to 90% by weight, preferably 10 to 70% by weight, more preferably about 20 to 50% by weight. May be.
  • the proportion of the component (C) is, for example, 0.001 to 90% by weight, preferably 0.001 to 80% by weight, more preferably 0.1 to 70% by weight (for example, 1 to 50% by weight), usually about 0.01 to 50% by weight (for example, 0.1 to 30% by weight), or about 1 to 90% by weight It may be.
  • the dose (or intake or dose) of component (A) and / or component (B) (and component (C)) can be selected from the same range as described above.
  • the bone crushing extract (bone crushing water extraction) used what was obtained as follows.
  • the object recognition memory test was performed as follows. ⁇ Object recognition memory test>
  • the object recognition memory test is a test using a habit of showing interest in new things by animals. That is, in the test stage, it is a test for confirming whether or not the object seen in the training stage is remembered.
  • the test was performed as described in the literature (Int J Neurosci, 121, pp.181-190, 2011. and Int J Neurosci, 121, pp.641-648, 2011.). Specifically, it was performed as follows.
  • the test was conducted in a relatively well-lit room (approximately 100 lux). Appropriate time intervals between the training phase and the test phase were determined in advance by testing with different groups of mice. There are no landmarks on the inner wall of the open field box under test.
  • the training phase place two identical objects in the field and let them search for 10 minutes.
  • one of the objects is replaced with a new object, but the place is not changed, and a 10-minute exploratory action is performed.
  • the increase in the number of times the mouse performs an exploratory action with interest in the replaced new object is used as an index of the object memory ability.
  • the ratio (%) of the number of searches for a new object with respect to the total search time is calculated as a search index (Preference index).
  • Example 1 Naringenin and naringenin-7'-O-glucuronide, one of the glycosides of naringenin, were synthesized in order to investigate the activity against nerve cells. First, projections on normal cortical neurons The extension action was examined. On the third day of culture of primary cultured mouse cerebral cortical neurons, each compound was treated at a concentration of 0.01, 0.1, 1, 10 ⁇ M, and after 4 days, the cells were fixed, and then axons (pNF ⁇ The length per cell (H positive) was examined by immunostaining.
  • Example 2 In Example 1, in addition to the synthesized naringenin and naringenin-7′-O-glucuronide, naringenin-4′-O-glucuronide, which is a glycoside of naringenin, was synthesized, and axon of A ⁇ (25-35) was synthesized. The stretching action was examined as follows.
  • osteoprosthesis known to contain naringenin was examined.
  • Example 3 After the novel object recognition test, each mouse was anesthetized and transcardially perfused with chilled saline. The whole brain was carefully removed from the skull, soaked in 4% paraformaldehyde overnight, then soaked in 30% sucrose-PBS and stored at ⁇ 30 ° C. Brains were cut into 20 ⁇ m continuous coronal sections using a cryostat (CM3050S, Leica, Heidelberg, Germany).
  • Fluorescence images of axons and A ⁇ (1-40 / 42) were taken at 324 ⁇ m ⁇ 430 ⁇ m using a fluorescence microscope (BX-61).
  • the area of extracellular amyloid plaques was measured using image analysis software ImageJ (http://rsbweb.nih.gov/ij).
  • ImageJ image analysis software
  • the bone replenishment extract was dissolved in physiological saline and orally administered once daily to 5XFAD mice (6-8 months old, male and female) at a dose of 500 mg / kg / day for 31 days.
  • the amount of the drug solution to be administered orally was 10 ml / kg body weight.
  • amyloid plaques are not observed in wild-type mice in any part of the prefrontal cortex, periorbital cortex, hippocampal CA1, and hippocampal dentate gyrus, whereas 5 ⁇ FAD mice It was increasing.
  • the amyloid plaque area significantly decreased in the osteoclastic rehydration extract 500 mg / kg administration group.
  • the degenerated axon was wild in any part of the prefrontal cortex, periolfactory cortex, hippocampal CA1, and hippocampal dentate gyrus. It was not observed in type mice, but increased in 5XFAD mice. In the osteoclastic rehydration extract 500 mg / kg administration group, a tendency to decrease this was shown.
  • Example 4 The bone replenishment extract was dissolved in physiological saline and orally administered to 5XFAD mice (45 weeks old, male) once a day at a dose of 500 mg / kg / day.
  • 5XFAD mice 45 weeks old, male
  • a 5XFAD mouse group 45 weeks old, male
  • a wild type mouse group 45 weeks old, male
  • the amount of drug solution to be administered orally was 10 ml / kg body weight.
  • the administration period was 22 days.
  • An object recognition memory test was performed on these mice, and after confirming that a memory improving effect was observed in the bone-fed rehydration extract administered group, the cerebral cortex of the mice was extracted after refluxing and lysate was prepared.
  • the direct binding protein search experiment of the osteoclast rehydration extract found the involvement of Collapsin response mediator protein-2 (CRMP2, also known as dihydropyrimidinase-related protein 2, TOAD-64) protein prior to this example.
  • CRMP2 Collapsin response mediator protein-2
  • the degree of CRMP2 phosphorylation in cerebral cortical lysate was examined by Western blotting.
  • the antibody used was an antibody that detects phosphorylation of threonine of the 514th amino acid of CRMP2.
  • CRMP2 phosphorylation was enhanced in the 5XFAD mouse solvent-administered group compared to wild-type mice, whereas CRMP2 phosphorylation was significantly decreased in the 5XFAD mouse administered with the crushed water extract. did. Reduction of CRMP2 phosphorylation has already been recognized as a mechanism that leads to promotion of axonal extension. Therefore, suppression of CRMP2 phosphorylation in the mouse brain by administration of a bone replenishing water extract is associated with axonal elongation and It is clear that this is part of the mechanism of memory enhancement.
  • Example 5 The components contained in the osteoclastic prosthesis were analyzed, and which components can contribute to axonal extension was examined as follows.
  • the bone replenishing water extract was dissolved in sterilized purified water.
  • Mouse cerebral cortical neurons were prepared from embryonic day 14 ddY mice.
  • the crushed rehydration extract was further fractionated into a petroleum ether fraction, an ethyl acetate fraction, an n-butanol fraction, and a water-soluble fraction.
  • the axon density was significantly decreased in A ⁇ 25-35 cells compared to A ⁇ 25-35 untreated cells.
  • Axon extension tendency was observed in all fractions, but axons were significantly extended especially by the post-treatment of the n-butanol fraction (10 ⁇ g / mL).
  • Example 6 The n-butanol fraction obtained in Example 4 was analyzed in detail, and the components that can contribute to axonal extension at the compound level were examined as follows.
  • n-butanol fraction was subdivided with silica gel to isolate five compounds, which were naringenin (1), neoeriocitrin (2), 5,7-dihydroxychromone-7-O-neohe It was identified from the results of LC-MS mass analysis that it was spidoside (4) and protocatechuic acid (5).
  • the LC-MS chart of the n-butanol fraction is shown in FIG. 13, and the structure of each identified compound is shown in the following formula.
  • a ⁇ 10 ⁇ M A ⁇ (25-35) was treated on the 3rd day of culture of primary cultured mouse cerebral cortical neurons, and 3 days later, 5 compounds each were treated at a concentration of 1 or 10 ⁇ M. After fixing the cells one day later, the length per cell of axons (pNF-H positive) and dendrites (MAP2 positive) was examined by immunostaining.
  • the axon density was significantly decreased in the A ⁇ 25-35 cells compared to the A ⁇ 25-35 untreated cells, but the treatment with the compounds 1 to 5 extended the axons. .
  • neoeriocitrin compound 2
  • compound 4 which is a glycoside of caffeic acid
  • Example 7 Dissolve bone replenishment extract in physiological saline and administer once a day at a dose of 500 mg / kg / day, or dissolve elephant leaf water extract in physiological saline once a day as 500 mg / kg / day, Alternatively, a bone replenishing water extract (500 mg / kg / day) and an Ekogi leaf water extract (50 mg / kg / day) were orally administered to 5XFAD mice once a day at the same time.
  • a bone replenishing water extract 500 mg / kg / day
  • an Ekogi leaf water extract 50 mg / kg / day
  • Ezoukogi leaf extract was used by freeze-drying a filter obtained by infiltrating the leaves of Eleutherococcus senticosus in the family Urugiaceae into water at 85 degrees for 30 minutes and filtering.
  • mice 5XFAD mice were female, 27-56 weeks old, and wild-type mice in the control group were female, 52 weeks old.
  • the amount of the drug solution to be administered orally was 10 mL / kg body weight.
  • the administration period was 15 days.
  • An object recognition memory test was performed on these mice. The interval between the training stage and the test stage was set to two conditions of 1 hour (Test 1) and 24 hours (Test 2).
  • Ezoukogi leaf water extract was dissolved in physiological saline and administered orally to normal mice (ddY, male, 7 weeks old) once a day at a dose of 500 mg / kg / day.
  • the amount of the drug solution to be administered orally was 10 mL / kg body weight.
  • the administration period was 27 days.
  • Ezoukogi leaf water extract was used by freeze-drying a leaf of Eleutherococcus senticosus belonging to the family Urugiaceae infiltrated with water at 85 degrees for 30 minutes. An object recognition memory test was performed on these mice. Training was performed on the 24th day after administration, and the test was performed on the 27th day after administration. The training and test interval was 72 hours.
  • an agent or composition useful for improving or improving memory ability and cognitive function can be obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention fournit un agent efficace dans l'amélioration des facultés de mémorisation, et des fonctions cognitives, ou similaire. L'agent de l'invention est configuré par au moins une sorte de composant choisie parmi : au moins une sorte de composant (A) choisie parmi une naringénine, un ériodictyol, un 5,7-dihydroxychromone, un acide caféique, un acide protocatéchique, un glycoside, et un sel de ceux-ci ; et un composant ginseng sibérien (B).
PCT/JP2016/074130 2015-08-18 2016-08-18 Agent reconstructeur/activateur de réseau neuronal WO2017030167A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017503639A JP6165380B1 (ja) 2015-08-18 2016-08-18 神経回路網の再構築・賦活剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-161125 2015-08-18
JP2015161125 2015-08-18

Publications (1)

Publication Number Publication Date
WO2017030167A1 true WO2017030167A1 (fr) 2017-02-23

Family

ID=58051875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/074130 WO2017030167A1 (fr) 2015-08-18 2016-08-18 Agent reconstructeur/activateur de réseau neuronal

Country Status (2)

Country Link
JP (2) JP6165380B1 (fr)
WO (1) WO2017030167A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181135A1 (fr) * 2017-03-31 2018-10-04 株式会社サン・クロレラ Procédé de production d'un agent améliorant l'efficacité d'apprentissage et composition de produit alimentaire améliorant l'efficacité d'apprentissage, et technologie associée
EP3572085A1 (fr) * 2018-05-25 2019-11-27 Neuro-Sys Composition de combinaison synergétique comprenant une saponine stéroïdique, premier composé polyphénolique et éventuellement, second composé polyphénolique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161606A (ja) * 2005-12-09 2007-06-28 Univ Of Tokyo 哺乳動物の海馬におけるニューロン新生を促進する組成物
JP2007230878A (ja) * 2006-02-27 2007-09-13 Pokka Corp 脳機能改善剤及びそれを含有する脳機能改善組成物
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
WO2014112145A1 (fr) * 2013-01-21 2014-07-24 レジリオ株式会社 Agent thérapeutique et procédé thérapeutique concernant 1,25d3-marrs pour une maladie neurologique telle que la maladie d'alzheimer
JP2016027031A (ja) * 2014-07-01 2016-02-18 レジリオ株式会社 神経回路網の再構築・賦活用医薬または食品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
CN102078423B (zh) * 2010-12-29 2012-07-25 陈永洪 一种治疗骨质增生的外用中草药制剂
US10272091B2 (en) * 2013-11-12 2019-04-30 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof
CN104825555B (zh) * 2015-04-23 2018-06-01 贵阳中医学院 一种治疗帕金森病的药物、制备方法及制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
JP2007161606A (ja) * 2005-12-09 2007-06-28 Univ Of Tokyo 哺乳動物の海馬におけるニューロン新生を促進する組成物
JP2007230878A (ja) * 2006-02-27 2007-09-13 Pokka Corp 脳機能改善剤及びそれを含有する脳機能改善組成物
WO2014112145A1 (fr) * 2013-01-21 2014-07-24 レジリオ株式会社 Agent thérapeutique et procédé thérapeutique concernant 1,25d3-marrs pour une maladie neurologique telle que la maladie d'alzheimer
JP2016027031A (ja) * 2014-07-01 2016-02-18 レジリオ株式会社 神経回路網の再構築・賦活用医薬または食品

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BAI YANJING ET AL.: "Active components from Siberian ginseng (Eleutherococcus senticosus) for protection of amyloid beta (25-35)-induced neuritic atrophy in cultured rat cortical neurons", J NAT MED, vol. 65, 2011, pages 417 - 423, XP019917565 *
CHIHIRO TODA ET AL.: "Shigoka Methanol Ekisu ni Yoru Synapse Saikeisei Sayo to Kioku Shogai Kaizen Sayo", ABSTRACTS OF ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, vol. 126, 2006, pages 130 *
CUI JIAN QUN ET AL.: "Continual Naringin Treatment Benefits the Recovery of Traumatic Brain Injury in Rats Through Reducing Oxidative and Inflammatory Alterations", NEUROCHEM RES, vol. 39, 2014, pages 1254 - 1262, XP055366285 *
HEO JIN HO ET AL.: "Effect of Antioxidant Flavanone, Naringenin, from Citrus junos on Neuroprotection", J. AGRIC. FOOD CHEM., vol. 52, 2004, pages 1520 - 1525, XP055366274 *
KHAN BADRUZZAMAN M. ET AL.: "Naringenin ameliorates Alzheimer's disease(AD)-type neurodegeneration with cognitive impairment(AD- TNDCI) caused by the intracerebroventricular- streptozotocin in rat model", NEUROCHEMISTRY INTERNATIONAL, vol. 61, 2012, pages 1081 - 1093, XP055366273 *
KUMAR PUNEET ET AL.: "Protective effect of hesperidin and naringin against 3- nitropropionic acid induced Huntington's like symptoms in rats: Possible role of nitric oxide", BEHAVIOURAL BRAIN RESEARCH, vol. 206, 2010, pages 38 - 46, XP026709951 *
LEEM EUNJU ET AL.: "Naringin protects the nigrostriatal dopaminergic projection through induction of GDNF in a neurotoxin model of Parkinson's disease", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 25, 2014, pages 801 - 806, XP028851753 *
RONG WEI ET AL.: "Naringin Treatment Improves Functonal Recovery by Increasing BDNF and VEGF Expression, Inhibiting Neuronal Apoptosis After Spinal Cord Injury", NEUROCHEM RES, vol. 37, 2012, pages 1615 - 1623, XP035079120 *
WANG MEI DONG ET AL.: "Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer's Disease", INT. J. MOL. SCI., vol. 14, 2013, pages 5576 - 5586, XP055366278 *
WONG CHUN KA ET AL.: "Drynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone", BRITISH JOURNAL OF NUTRITION, vol. 110, 2013, pages 475 - 485, XP055366287 *
XINLUAN WANG ET AL.: "Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of Drynaria fortunei-An in vitro efficacy study", PHYTOMEDICINE, vol. 18, 2011, pages 868 - 872, XP028096890 *
YANG YOU ZHI ET AL.: "Active Constituents from Drynaria fortunei Rhizomes on the Attenuation of Abeta25-35-Induced Axonal Atrophy", NATURAL PRODUCT, vol. 78, 24 August 2015 (2015-08-24), pages 2297 - 2300, XP055366291 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181135A1 (fr) * 2017-03-31 2018-10-04 株式会社サン・クロレラ Procédé de production d'un agent améliorant l'efficacité d'apprentissage et composition de produit alimentaire améliorant l'efficacité d'apprentissage, et technologie associée
JPWO2018181135A1 (ja) * 2017-03-31 2020-02-06 株式会社サン・クロレラ 学習効果改善剤及び学習効果改善用食品組成物の製法並びにその関連技術
JP7127782B2 (ja) 2017-03-31 2022-08-30 株式会社サン・クロレラ 学習効果改善剤及び学習効果改善用食品組成物の製法並びにその関連技術
EP3572085A1 (fr) * 2018-05-25 2019-11-27 Neuro-Sys Composition de combinaison synergétique comprenant une saponine stéroïdique, premier composé polyphénolique et éventuellement, second composé polyphénolique
WO2019224388A1 (fr) * 2018-05-25 2019-11-28 Neuralia Composition de combinaison synergétique comprenant une saponine stéroïdienne, un premier composé polyphénolique et un second composé polyphénolique
US11951113B2 (en) 2018-05-25 2024-04-09 Neuralia Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and a second polyphenolic compound

Also Published As

Publication number Publication date
JPWO2017030167A1 (ja) 2017-08-17
JP2017165775A (ja) 2017-09-21
JP6165380B1 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
CN102762573B (zh) 用于在神经退行性障碍中保护脑部健康的化合物、组合物和方法
JP5207611B2 (ja) 糖化阻害剤
US20150231162A1 (en) Fructose absorption inhibitor
WO2005072684A1 (fr) Procédé de production de l'extrait de maca
KR102038810B1 (ko) 성장 호르몬 분비 촉진제
US20230125075A1 (en) Composition Containing Paper Mulberry Extracts
EP2135616B1 (fr) Fruit d'airelle séché destiné à influencer l'état de l'intestin
US20190070129A1 (en) Composition comprising panduratin or fingerroot (boesenbergia pandurata) extract for treating, preventing, or ameliorating bone loss disease
JP6165380B1 (ja) 神経回路網の再構築・賦活剤
JPWO2005074961A1 (ja) 体脂肪調整剤
JP7385325B2 (ja) ロコモティブシンドローム改善用組成物
JP2016027031A (ja) 神経回路網の再構築・賦活用医薬または食品
WO2015083554A1 (fr) CRISTAUX DE 4G-O-α-D-GLUCOPYRANOSYLRUTINE ET LEUR APPLICATION
US9527879B2 (en) Aster glehni extracts, fractions or compounds isolated therefrom for the treatment or prevention of hyperuricemia or gout
JP6122200B1 (ja) 抗糖化用組成物
KR20150117514A (ko) 달맞이꽃 추출물을 유효성분으로 함유하는 미소중력하 또는 신경손상으로 인한 근위축 예방 또는 치료용 약학 조성물
JP2007031297A (ja) 美白用組成物
JP2005281272A (ja) 末梢血流改善剤
JP6964290B2 (ja) Ａｔｐ産生促進用剤
KR100640094B1 (ko) 콜레스테롤 저하 또는 항산화 활성을 갖는 녹차씨유를 포함하는 조성물
JP4672304B2 (ja) 脂肪分解促進剤
KR101862135B1 (ko) 신규한 디노익산 화합물 및 이를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물
KR101468288B1 (ko) 두충피 추출물 또는 이의 분획물을 포함하는 파킨슨 질환의 예방 또는 치료용 약학적 조성물
JPWO2018124258A1 (ja) 慢性疲労症候群の治療剤
KR20130059741A (ko) 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2017503639

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16837156

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16837156

Country of ref document: EP

Kind code of ref document: A1